BrightFocus Foundation Congratulates the 2013 Geoffrey Beene Global NeuroDiscovery Challenge Winners!
In only five days, you and thousands of other participants cast nearly 6,300 votes, demonstrating a powerful reminder of the need for a better understanding of gender-based differences in Alzheimer’s diagnosis and treatment.
Thank you for making the Geoffrey Beene 2013 Global NeuroDiscovery Challenge a success, and for being part of the movement to end Alzheimer’s disease!
First Place Winner
- Enrico Glaab, Ph.D., who today won the $50,000 Geoffrey Beene Global NeuroDiscovery Challenge for research proposals on gender differences in Alzheimer’s disease. Glaab, of the Luxembourg Centre for Systems Biomedicine at the University of Luxembourg, will examine whether certain genes are expressed differently in men and women, and whether one gene (USP9Y) may be protective in men, explaining the increased risks for Alzheimer’s disease in women.
Second Place Winner
- Sanofi Pharmaceuticals also announced a $50,000 award for the second place entry, by John Quakenbush, Ph.D., and Kimberly Glass, Ph.D., of the Dana-Farber Cancer Institute at the Harvard School of Public Health. Quakenbush and Glass will examine gender differences in cellular networks, and hope to expand technology they have developed to better predict sex-based differences in Alzheimer’s disease.
Enrico Glaab, Ph.D.
Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Luxembourg
Male/Female Differences in Aging Brains in a Gene For Ubiquitin-Specific Peptidase 9 (USP9) as a Possible Cause for Increased Incidence of Alzheimer’s Disease in Older Women
Aging is considered one of the primary risk factors for Alzheimer’s Disease. Studies of the aging human brain show that changes in gene expression may be different between men and women. This investigator analyzed two datasets and looked for genes that are deregulated only in aging men and only in aging women in Alzheimer’s compared to unaffected controls.
Aging is considered one of the primary risk factors for Alzheimer’s disease. Studies of the aging human brain show that changes in gene expression may be different between men and women. Preliminary data suggested that a number of genes expressed differed according to sex and Alzheimer’s diagnosis. Top amongst these was a gene, USP9Y, only present on men’s Y chromosomes. Supportive findings come from other studies that show that USP9 is known for involvement in multiple pathways related to Alzheimer’s. These include the well-known Tau protein, a hallmark of Alzheimer’s, as well as SIRT1, a gene also linked with more general longevity. The innovative hypothesis is that USP9Y is important to men and may be protective against Alzheimer’s disease, perhaps explaining increased risks in women. Dr. Glaab and his team will seek to verify and these findings by data-mining other datasets in males only and also extending this work to cell cultures and animal mouse models.
John Quackenbush, Ph.D. and Dr. Kimberly Glass, Ph.D.
Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, MA
Male/Female Differences in Alzheimer’s Disease Have Unique Changes in Cellular Networks
A cell’s health is defined by complex networks of interacting elements. Traditional research has been hampered by difficulties in relating stresses on one network to effects in distant, but related networks. Building on earlier work, this project hypothesizes that network differences can identify male and female features of healthy brain tissue. Further, the preliminary findings suggest that male and female networks are different when healthy, but break down, becoming similar as Alzheimer’s progresses. The innovation of their technology, PANDA (Passing Attributes between Networks for Data Assimilation) lies in its predictive ability, anticipating unexpected communication between networks. As new data sources are gathered, the models update and provide a more complete picture of nuanced activities that can explain the overall biological response.Their proposal seeks to expand their technology to new databases in order to better predict sex-based differences in Alzheimer’s.
Herve Rhinn, Ph.D. and Asa Abeliovich, M.D., Ph.D.
Department of Pathology, Columbia University
SCARB1 as a Mediator Of Male/Female Differences in Alzheimer’s Disease
In biology, it’s important to separate differences that cause disease from those that are simply a disease symptom. This team applied this question to examining gene expression databases for sex-based differences in Alzheimer's disease patients and healthy brains. In doing so, they identified a previously unstudied gene, SCARB1. SCARB1 facilitates cholesterol distribution, a process that has long been implicated in Alzheimer's disease. To predict the importance of SCARB1, they developed a process that ranks the importance of finding different numbers of given molecules against other factors like whether that molecule interacts with other differentially expressed genes. The innovation is around a set of computational tools that allow researchers to cut through a fog of data to find genes whose changes happen early in the course of the disease. This project proposes to expand their analysis to new datasets, and begin the process of testing SCARB1 for association with Alzheimer's disease in living systems.
Last Review: 11/06/13